PharmaResearch Co., Ltd. operates as a biopharmaceutical company in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; Rejuvenex cream, which treats the wound through rapid tissue regeneration; REJURAN HEALER, an intra dermal injection to enhance elasticity, turgidity, and tonicity of skin; Rejuran i and Rejuran s intra dermal or cannula injections; REJURAN moisturizer for daily skin protection; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel; REJURAN healing cream and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. It also provides D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; and CLEVIEL prime plus and contour plus with lidocaine medical devices, as well as CONJURAN medical devices. In addition, the company offers functional foods under the REJULINE, REJUSHINE, and REJULIGHT brands. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Seongnam, South Korea.
PharmaResearch Dividend Announcement
• PharmaResearch announced a annually dividend of ₩660.00 per ordinary share which will be made payable on 2024-04-18. Ex dividend date: 2023-12-27
• PharmaResearch annual dividend for 2023 was ₩660.00
• PharmaResearch's trailing twelve-month (TTM) dividend yield is 0.28%
• PharmaResearch's payout ratio for the trailing twelve months (TTM) is 11.80%
PharmaResearch Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2023-12-27 | ₩660.00 | annually | 2024-04-18 |
2022-12-28 | ₩660.00 | annually | 2023-04-14 |
2016-12-28 | ₩300.00 | annually | |
2015-12-29 | ₩200.00 | annually |
PharmaResearch Dividend per year
PharmaResearch Dividend growth
PharmaResearch Dividend Yield
PharmaResearch current trailing twelve-month (TTM) dividend yield is 0.28%. Interested in purchasing PharmaResearch stock? Use our calculator to estimate your expected dividend yield:
PharmaResearch Financial Ratios
PharmaResearch Dividend FAQ
Other factors to consider when evaluating PharmaResearch as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy PharmaResearch stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: PharmaResearch's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, PharmaResearch publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, PharmaResearch distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from PharmaResearch are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: PharmaResearch sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, PharmaResearch distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: PharmaResearch declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of PharmaResearch's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review PharmaResearch's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.